Technology

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Published

1 year ago

February 26, 2025

MENLO PARK, Calif., Feb. 26, 2025 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units (“RSUs”) underlying an aggregate of 108,450 shares of GRAIL’s common stock to 15 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL’s Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over an approximately four year period, with 25% of the award vesting Feb. 28, 2026, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302385398.html

SOURCE GRAIL, Inc.

Technology

IGCS International Announces Strategic Equity Investment by Lacks Enterprises

Published

11 minutes ago

April 22, 2026

DALLAS, April 22, 2026 /PRNewswire/ — IGCS International, a CVE-certified SDVOSB and leading provider of mission support and MRO supplies to the U.S. Department of Defense and federal agencies, today announced that Lacks Enterprises has acquired an equity stake in the company.

The strategic investment combines IGCS’s expertise in government supply chain, logistics, and MRO solutions with Lacks Enterprises’ advanced manufacturing capabilities, including electroplating, injection molding, composites, and testing for aerospace and defense.

“IGCS has built a strong track record supporting the Department of Defense… Partnering with Lacks Enterprises allows us to integrate cutting-edge manufacturing innovation into our offerings,” said Russ Spears, President of IGCS International.

Media Contact: Russ Spears, 214-733-7278, russ@igcsintl.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/igcs-international-announces-strategic-equity-investment-by-lacks-enterprises-302750824.html

SOURCE IGCS International

Technology

Shoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026

Published

11 minutes ago

April 22, 2026

GRAND RAPIDS, Mich., April 22, 2026 /PRNewswire/ — Shoulder Innovations, Inc. (“Shoulder Innovations”) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the first quarter of 2026 after market close on Wednesday, May 13, 2026.

Management will host a conference call to discuss financial results beginning at 4:30 p.m. ET / 1:30 p.m. PT on May 13, 2026. Those interested in listening to the conference call may do so by dialing (877) 407-8216 for domestic callers or (412) 902-1015 for international callers and providing access code 13759613. A live and archived webcast of the event will be available in the “Investor Relations” section of the Shoulder Innovations website at https://ir.shoulderinnovations.com/.

About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations’ ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations’ ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

Contact
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shoulder-innovations-to-report-first-quarter-2026-financial-results-on-may-13-2026-302750154.html

SOURCE Shoulder Innovations

Technology

Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026

Published

11 minutes ago

April 22, 2026

MADISON, Wis., April 22, 2026 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 6, 2026.

The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call’s conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (international), conference ID: 4178502.

A live webcast of the call will also be available from the Investor Relations section of the company’s website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the fourth quarter of fiscal 2026.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Investor and Media Contact
Steve Monroe
VP, Financial Planning & Analysis, Accuray
Investor.relations@accuray.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-to-report-third-quarter-fiscal-2026-financial-results-on-may-6-2026-302750641.html

SOURCE Accuray Incorporated